1) Attal N, Cruccu G, Haanpää M, et al:EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13:1153-1169, 2006
2) Baron R, Freynhagen R, Tölle TR, et al:The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 150:420-427, 2010
3) Bian F, Li Z, Offord J, et al:Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord:an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res 1075:68-80, 2006
4) Bockbrader HN, Wesche D, Miller R, et al:A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49:661-669, 2010
5) Dworkin RH, O'Connor AB, Backonja M, et al:Pharmacologic management of neuropathic pain:evidence-based recommendations. Pain 132:237-251, 2007
6) Edelsberg J, Oster G:Summary measures of number needed to treat:how much clinical guidance do they provide in neuropathic pain? Eur J Pain 13:11-16, 2009
7) IASP (http://www.iasp-pain.org)
8) 井上真輔,牛田享宏,西原真理・他:痛みとしびれのサイエンス―基礎と臨床:学際的痛みセンター.脊椎脊髄24:558-563,2011
9) Moulin DE, Clark AJ, Gilron I, et al:Pharmacological management of chronic neuropathic pain--consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 12:13-21, 2007
10) Saldaña MT, Navarro A, Pérez C, et al:Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin:evidence from medical practice in primary care settings. Rheumatol Int 30:1005-1015, 2010
11) Taylor CP, Garrido R:Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (alpha2-delta) type 1 protein. Neuroscience 155:510-521, 2008